Competitive research grants for Michiel Vermeulen

Michiel Vermeulen, Faculty of Science, theme Cancer development and immune defense, obtained three competitive research grants, two from NWO (ENW-GROOT and ENW-KLEIN2) and a ZonMW Open Program Grant. These innovative projects address diverse topics related to development and disease and will make use of various state of the art omics technologies such as single cell RNA sequencing and interaction proteomics.

ZonMw Open Competition grant

Defining H3K9 methylation regulatory pathways in monocyte and macrophage function in cardiovascular disease (with Menno de Winther, AMC).
Total grant: 750 kEuro. Awarded Faculty of Science: 375 kEuro.

By the end of this decade cardiovascular disease (CVD) will have become the major clinical and socio-economic problem worldwide, largely driven by the aging population and the global obesity epidemic. Current medication reduces CVD risk only by 35% at best, and despite major efforts by the pharmaceutical industry drug pipelines are drying up.

This emphasizes the need for novel strategies for CVD management, targeting disease mechanisms beyond cholesterol, hypertension or coagulation. The predominant immune cells in atherosclerotic disease, monocytes and macrophages play a central role in shaping atherosclerotic disease, in that they 1) strongly influence plaque growth and stability and 2) regulate the patient’s systemic inflammatory status, both of which are key determinants of “patient-vulnerability”. It follows therefore that this renders them an eminent target for intervention.

Although the recent CANTOS trial clearly demonstrated the potential of targeting inflammation in CVD, antibody mediated blockade in patient groups may be hampered by costs and side-effects (e.g. infections).

Further defining relevant inflammatory processes will thus allow better-tailored therapies.

In this program we aim at defining epigenetic processes that contribute to CVD and are amendable for therapeutic intervention. Our exiting recent data has identified KDM3A, a regulator of repressive histone-3 lysine 9 (H3K9) methylation, as a relevant epigenetic enzyme that controls macrophage activation and impacts on human atherosclerotic disease. However, the regulatory mechanisms that control KDM3A and the highly dynamic (and reversible) H3K9 methylation are unknown.

We hypothesize that by regulating repressive H3K9 methylation in monocytes and macrophages KDM3A is a key determinant of macrophage function in cardiovascular disease progression. Applying an innovative combination of monocyte and macrophage biology in CVD (de Winther lab) and state-of-the-art interaction proteomics (Vermeulen lab) we aim at defining the regulatory machinery that controls H3K9 methylation processes. We will apply a combination of RNAseq, ChIPseq, mass-spectrometry, proximity-labeling experiments with functional analysis of monocytes and macrophages during differentiation and activation to define regulatory interaction partners of KDM3A, map H3K9 methylation dynamics and relevant reader complexes and determine the impact of intervening in H3K9 methylating enzymes on cellular function in relation to human disease.

The unique combination of expertise will allow making progress on defining the regulation of epigenetic processes in macrophages. By understanding which epigenetic pathways and proteins play a role in regulating macrophage responses, we expect to define innovative leads to therapeutically reprogram monocyte and macrophage inflammatory responses in atherosclerosis and related chronic inflammatory disorders.

NWO open call GROOT grant

Single cell analysis of animal development.
Awarded Faculty of Science: 330 kEuro.

During development, a single fertilized egg creates tens to hundreds of highly specialized cell types, in great numbers, that together form a complete organism with well-defined tissues and organs. Critical in this process is that cells with identical genomes turn different sets of genes on and off to acquire specialized forms and functions, at the correct time and place. How gene expression is spatiotemporally controlled to determine cellular decisions and cell identity is a central question in biology, and key to understanding development, health and disease.

In recent years, large amounts of gene expression data have been generated, driven by massively parallel sequencing and including single-cell analyses. While such data have revealed developmental trajectories, understanding the underlying cellular decision making is far from trivial. Establishing causality and deciphering regulatory networks requires comprehensive quantitative analyses of not only the transcriptome, but also the epigenome, proteome, and chromatin association of transcription factors. To identify initiating events, these data are needed at a high temporal resolution, in individual cells as they progress through developmental decisions. In addition, computational modeling approaches are necessary to identify how feedback, feedforward, and other nonlinear interactions between the critical regulators together govern cellular decision making. Further, targeted disruptions are needed to reveal causality and to test and improve the model predictions. Such an integrative study of genome regulation in vivo goes beyond the expertise of individual research groups and current state-of-the-art. Therefore, we have assembled a consortium of experts in advanced single-cell technologies, proteomics, model animal genetics, and mathematical modeling, who will collaborate closely to reveal the regulatory logic of cellular decision making, based on detailed quantitative analyses of native cells.

Our joint effort will be focused on cell fate transitions in muscle and neuronal lineages in Caenorhabditis elegans, a model animal with reproducible development and efficient genetics. Over a short time course, multipotent precursor cells in the mesoblast and neuroblast lineages undergo a series of cell divisions, create descendants with alternative cell fates, decide between cell death or survival, and form terminally differentiated cell types. To reveal the underlying regulatory networks, we will 1) optimize strategies for epigenome analysis in single cells from C. elegans, 2) obtain single-cell epigenomics and transcriptomics data, 3) as well as cell-type specific quantitative proteomics data, for native mesoblast and neuroblast descendants during their progression from progenitor to differentiation, 4) use the obtained experimental data to develop dynamical, quantitative models of the core networks that control cellular decision making, and 5) experimentally test predictions arising from these models in lineage-specific mutants. Through a unique concerted effort, the consortium aims to acquire in-depth, mechanistic understanding of the control networks that organize developmental decision making in a living animal, with the ultimate goal to help identify innovative therapeutic opportunities to treat human diseases.

NWO Open Competition ENW-KLEIN grant

Synthetic affinity-based probes for proteome-wide identification of poly(ADP-ribosyl)-binding proteins.
Awarded Faculty of Science: 360 kEuro.

Adenosine diphosphate ribosylation is a common post-translational protein modification that is involved in various pathological processes such as cancer, age-related diseases and viral infections. It is important that we know what proteins can interact with adenosine diphosphate ribose chains if we are to design better medicines. In this study, different molecules that contain adenosine diphosphate ribose will be synthesized and subsequently used for interaction tests in extracts from human cells. Follow-up tests will also be carried out to identify proteins that bind with adenosine diphosphate ribose and that play a role in the cellular response to damage to DNA.

Adenosine diphosphate ribosylation is a common post-translational protein modification that is involved in various pathological processes such as cancer, age-related diseases and viral infections. It is important that we know what proteins can interact with adenosine diphosphate ribose chains if we are to design better medicines. In this study, different molecules that contain adenosine diphosphate ribose will be synthesized and subsequently used for interaction tests in extracts from human cells. Follow-up tests will also be carried out to identify proteins that bind with adenosine diphosphate ribose and that play a role in the cellular response to damage to DNA.

go to main content
Research Annual Report 2020 Grants

Highlights

Most significant

Numerous grants were acquired by our outstanding researchers. We are delighted with these accomplishments. The most significant grants awarded in 2020 are presented on this page.

EU Research project ImmUniverse for RIMLS scientists

Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies. read more

EU Research project ImmUniverse for RIMLS scientists

Transforming diagnosis and therapy of immune-mediated diseases.

Transdisciplinary consortium to focus on common biomarkers in Ulcerative Colitis and Atopic Dermatitis.
Total grant: 15,500 kEuro. Awarded Radboudumc: 1,000 kEuro.

Radboudumc collaborates with 25 European partners on dissecting common disease mechanisms of Ulcerative Colitis and Atopic Dermatitis in the new research project ImmUniverse, aimed at improving diagnostic and therapeutic options for patients living with these conditions. Through molecular and immune profiling techniques, the team will identify signatures of biomarkers and mechanistic principles which reveal information on disease severity and progression enabling personalised therapy decisions for each patient at the right time. The project was granted a budget of EUR 31 million provided by the Innovative Medicines Initiative (IMI 2), a joint initiative of the European Union and the EFPIA (European Federation of Pharmaceutical Industries and Associations), and is coordinated by Humanitas University in Milan.

Immune-mediated inflammatory diseases (IMIDs) are an increasing medical burden in industrialised countries worldwide. They are characterised by an enormous heterogeneity with regard to disease outcome and response to targeted therapies, which often cannot be adequately tailored to individual patients. Hence, an in-depth understanding of this heterogeneity and the biomarkers which predict disease control and therapy response over time are important prerequisites for future precision medicine strategies in IMIDs. The pathogenic components (“omics”) responsible for the disease outcome in each individual patient, i.e. environment, genes, gut microbiota or the immune system, are remarkably multifactorial, with thousands of constituents all interacting with and impacting on each other.

ImmUniverse has been formed as a European transdisciplinary consortium to tackle the unmet needs and pave the way towards a truly personalised disease understanding of two different IMIDs: Ulcerative Colitis and Atopic Dermatitis. Irma Joosten, local coordinator: "Through a unique collaboration between the departments dermatology, Elke de Jong, Ellen van den Bogaard), Gastroenterology Frank Hoentjen, and Medical Immunology, Hans Koenen, all theme Inflammatory diseases, we will be able, together with our consortium partners, to embark on an extensive cross-disease -omics quest, where we will systematically compare profiles and interactions between recirculating immune cells and the respective tissue microenvironment.  In a prospective study, and unlike previous studies in the field, we will specifically compare signatures from the same individual over time, capturing the full range of disease activity. The novel, circulating (immune)biomarker assays are expected to improve diagnosis, inform about disease severity and progression early in the clinical course, and enable treatment response and remission monitoring."

Dutch Cancer Society grant received by Annemiek van Spriel and Laia Querol-Cano

Cell surface protein organization determines therapeutic efficacy of cancer antibodies. read more

Dutch Cancer Society grant received by Annemiek van Spriel and Laia Querol-Cano

Research project, project # 12949. Cell surface protein organization determines therapeutic efficacy of cancer antibodies. Annemiek van Spriel and Laia-Querol-Cano, Cancer development and immune defence.
Awarded Radboudumc: 695 kEuro.

Immunotherapy using antibodies targeting the cell surface has led to important clinical advances in patients with cancer. Still, clinical responses of antibody-based therapies are limited to approximately 20-30% of cancer patients even in conjunction with chemotherapy and/or radiotherapy. One of the major scientific challenges in the oncology field is to increase our understanding why tumor cells escape from therapeutic antibodies.The aim of this project is to decipher how cell surface organization determines the efficacy of therapeutic antibodies against cancer. This will provide molecular and biological insight into the underlying mechanisms of antibody resistance, and facilitate development of a new class of therapeutic that modulates tumor cell surface organization.

Health Holland LSH-TKI grant for Ellen van de Bogaard

967 kEuro grant to develop organoids enabling new research methods for skin disorders. read more

Health Holland LSH-TKI grant for Ellen van de Bogaard

LSH-SGF Humane Meetmodellen 1.0: Platform for Alternative Skin Tests for sustainable FUTURE science - PAST4FUTURE. Ellen van den Bogaard, Inflammatory diseases.
Total grant: 694 kEuro. Awarded Radboudumc: 594 kEuro.

Under the leadership of Ellen van den Bogaard and colleagues of theme Inflammatory diseases, a large consortium is setting up a platform in which materials and technologies will be developed to stimulate research with so-called skin organoids, small pieces of cultured skin. The goal of this is to research the effect of these organoids on the skin and skin diseases. Also drugs can be tested in these organoids. For this purpose the researchers receive a grant of 967K euro from Health Holland.

A well functioning skin plays a very important role in our health. Unfortunately, many people suffer from skin diseases. In the Netherlands alone there are more than 2 million patients with serious chronic inflammatory skin diseases, such as psoriasis and atopic eczema. People's skin models offer many opportunities for research into skin function, skin diseases and drug testing. They are scientifically and ethically indispensable. However, the application of these skin models in fundamental science lags behind, because the standardized, commercially available skin models often turn out to be unsuitable for specific issues and research budgets are not sufficient for the large-scale use of these precious human measurement models.

PAST4FUTURE

That is why researchers from four Dutch experimental dermatology laboratories are setting up a new platform in this project: "Platform for alternative skin models for sustainable future science", or PAST4FUTURE for short. The platform aims to generate general, versatile and sustainable materials and technologies and make them accessible to everyone. Robust protocols should lead to reproducible results that will be tested within the project in the four separate laboratories.

DNA research using CRISPR Cas9

Principal investigator Ellen van den Bogaard explains: "We are going to make universal cells from inexhaustible sources (stem cells and immortal cell lines) in which, with the help of the powerful CRISPR Cas9 technology, we can process the hereditary material and study its effects in the tissue itself. For this new technology, international researchers received the Nobel Prize in Chemistry in 2020.

Ellen van den Bogaard continues: "This very first nationwide collaboration of experts in experimental dermatology and the contribution of major industrial partners will enable us to make these technologies available more quickly to both academic science and industry. This will make us less dependent on patients and experimental animals".

About PAST4FUTURE

The Platform for Alternative Skin Tests for sustainable Future science (PAST4FUTURE) is a consortium led by the Radboudumc. This project is carried out together with Huiqing (Jo) Zhou of the department for Molecular Developmental Biology (FNWI-RU) and external partners: VU University Medical Center, Leiden University Medical Center, Association of Cooperating Burns Centers in the Netherlands, CELLnTEC Advanced Cell Systems AG and TropIQ Health Sciences.

1,600 kEuro for COHERENT to improve the diagnosis and treatment of blood cancer

New diagnostic technologies will be developed for rare hematological cancers. read more

1,600 kEuro for COHERENT to improve the diagnosis and treatment of blood cancer

COHERENT: COrrect diagnosis of HEmatological cancers for Right Treatment Decisions
Total grant: 1,600 kEuro. Awarded Radboudumc: 800 kEuro.

Hematologic malignancies come in very different forms varying from lymphoma, leukemia to multiple myeloma. Most of these malignancies classify as rare cancers but together they rank number 5 (following lung cancer) as most frequently occurring malignancy in the Netherlands. Due to their rare but also extremely heterogeneous nature a correct diagnosis is often difficult to make. This is further hampered by the fact that >20% of healthy individuals above the age of 65 carry acquired mutations in genes underlying blood cancer.

Under the umbrella of the COHERENT platform new diagnostic technologies will be developed for rare hematological cancers. Project leader Bert van der Reijden, associate professor in molecular hematology, Dept Laboratory Medicine: “Diagnostic developments evolve extremely rapidly. At a nationwide level large differences exist as to their use and clinical applicability. We will capitalize on institutional developments through COHERENT, for COrrect diagnosis of HEmatological cancers for Right treatmENT decisions. Our expertise will be exchanged to improve diagnostic tests across different hematological disease entities. In parallel, we will develop, validate and exchange new technologies to further the diagnosis of hematologic malignancies. Generated data will be centrally stored and will be made accessible to investigators in the field. To create awareness among patients, diagnostic improvements and the use thereof will be communicated to Dutch patient organizations. Financial support from KWF will last until 2026. After this period the platform will continue to improve the diagnosis and treatment of patients with hematological cancers.”

Koen van den Dries received two grants from NWO

He will investigate the movement of tumor cells and the molecular mechanisms of metastasis. read more

Koen van den Dries received two grants from NWO

NWO Open Competition ENW-KLEIN grant

Molecular mechanisms of actin isoform usage in cancer cell migration. 
Awarded Radboudumc: 350 kEuro.

Metastases occur when cancer cells move from the original tumour to another tissue. Although we know that metastases are caused by the mobility of cancer cells, ways to prevent metastases are limited. More knowledge is therefore needed about the means by which cancer cells move. The movement of cancer cells is regulated by their skeletons and this project will investigate the role small differences in the building blocks of this skeleton play in the movement of cancer cells. We expect better definition of these differences to lead to more options for preventing metastases in the future.

NWO Open Competition Domain Science XS grant

Small differences, large impact: how actin variants differentially control cancer cell migration.
Awarded Radboudumc: 50 kEuro.

NWO ENW-XS category strives to encourage curiosity-driven and bold research involving a relatively quick analysis of a promising idea. In this project, Koen van den Dries, theme nanomedicine, will investigate the movement of tumor cells and the molecular mechanisms of metastasis. Metastases arise when cancer cells leave the primary tumor site and colonize distant tissues. While it is known that metastases are driven by cancer cell movement, possibilities to prevent metastases are limited. It is therefore essential to increase our understanding of cancer cell movement, which is regulated by the cellular skeleton. Here, we aim to develop innovative gene engineered cell systems to investigate the importance of small differences in the building blocks of this skeleton in regulating cancer cell movement. We expect that a better insight into these differences will in the future lead to more possibilities to prevent metastases.

Competitive research grants for Michiel Vermeulen

Michiel Vermeulen, Faculty of Science, obtained three competitive research grants, two from NWO and a ZonMW Open Program grant. read more

EJP-RD grants for several RIMLS researchers

Clara van Karnebeek, Werner Koopman and Jo Zhou received each funding from the European Joint Programme on Rare Diseases. read more

EJP-RD grants for several RIMLS researchers

These research groups received funding from the European Joint Programme on Rare Diseases of 250 kEuro each to enable scientists to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with a clear benefit for patients. 

Changing rare disorders of LysInE metabolism – CHARLIE. Clara van Karnebeek and Karlien Coene, Metabolic disorders.
Total grant: 1,200 kEuro. Awarded Radboudumc: 250 kEuro.

A reprogramming-based strategy for drug repositioning in patients with mitochondrial DNA-associated Leigh syndrome. Werner Koopmans, Metabolic disorders.
Total grant: 2,000 kEuro. Awarded Radboudumc: 250 kEuro.

Aniridia – Novel therapeutic tools to treat or prevent progressive cornea opacification. Jo Zhou, Reconstructive and regenerative medicine.
Total grant: 1,400 kEuro. Awarded Faculty of Science: 250 kEuro.

ZonMw Open Competition grant for team of Jolanda de Vries

Her research group will use the grants to establish new lines of research and foster collaborations to optimize the design of immunotherapies. read more

ZonMw Open Competition grant for team of Jolanda de Vries

Optimizing the design of dendritic cell vaccine immunotherapies. Jolanda de Vries, Gerty Schreibelt and Martijn Verdoes.
Total grant: 679 kEuro. Awarded Radboudumc: 548 kEuro.

The awarded research project will initiate new research lines and collaborations between various research groups. Amongst other things, this project will work on improving immune therapies against cancer and the role of genes in ageing processes.

In recent years, vaccination of cancer patients with peptides corresponding to cancer antigens with the aim of raising anti-cancer cytolytic T lymphocytes (CTL) responses. The efficacy of immune vaccines depends on how effective the peptide is cross-presented by dendritic cells (DCs) to activate CTLs. Goal of this project is to optimize the cross-presentation efficiency of cancer-specific MHC-I-binding epitopes by chemical modifications. We propose to unravel the cell-biological basis of cross-presentation of different antigen vaccine modalities by a combination of novel chemical approaches with state-of-the- art cell biology, microscopy and immunology. We envision that this study will lead to a universal strategy for designing optimal peptide-based anti-cancer vaccines. This novel directed approach will lead to a detailed understanding of CTL cross-priming and thereby allow for smart design strategies to optimize anti-cancer vaccination.

Martijn Verdoes has been awarded NWO and ICI grants

A NWO Toegepaste en Technische Wetenschappen, Open technologie programma (TTW OTP) grant and a grant from Institute for Chemical Immunology (ICI) for the ICI Amsterdam-Leiden-Nijmegen cancer vaccine consortium. read more

Martijn Verdoes has been awarded NWO and ICI grants

NWO TTW OTP grant

A nanomedicine platform to induce targeted eradication of tumors.
Awarded Radboudumc: 680 kEuro.

Summary NWO domain TTW’s website and online in ISAAC

Cancer evolves from normal cells and is usually recognized by our immune system and destroyed. Unfortunately, in some instances cancer cells escape and can even paralyze our immune system, resulting in outgrowth of tumours. Immunotherapy is aimed at reinforcing the anti-cancer immune response. We developed patient-derived dendritic cell vaccines to stimulate anti-cancer immunity upon re-injection of these educated immune cells. Unfortunately, generating individual cellular vaccines ex vivo for every patient in specialized clinical grade culture facilities is very expensive. We propose to circumvent this by developing nanomedicines for in vivo delivery. Nanoparticle- and antibody-based vaccines and immunomodulators will be developed that will reinforce the immune system to destroy cancer cells. We expect that this approach will provide ‘off the shelf’ nanomedicines that guarantee widespread clinical use.

ICI Amsterdam-Leiden-Nijmegen cancer vaccine consortium

Synthetic peptide conjugates for cancer therapy.
Total grant: 1,200 kEuro. Awarded Radboudumc: 305 kEuro.

The Chemical Immunology group from Martijn Verdoes, theme Nanomedicine, joined forces with two Organic Chemistry groups (Jeroen Codee and Dima Filippov) and a Chemical Biology group (Sander van Kasteren) from Leiden University, and Immunology groups at the AmsterdamUMC (Yvette van Kooyk) and the LUMC (Ferry Ossendorp) to form a consortium to develop new cancer vaccines.

Funding for this consortium was granted by the Institute for Chemical Immunology (ICI). Five PhD candidates will work in close collaboration to synthesize multimodal vaccine conjugates to specifically deliver tumor epitopes and immunomodulating adjuvants to dendritic cells with the aim to elicit specific T cell responses. Using state-of-the-art chemical strategies and super-resolution imaging techniques, conjugates bearing bioorthogonal trackable epitopes will be characterized at cell biological level.

This will provide valuable structure-activity relationship data when correlated to in vitro and in vivo immunological outcome, which will allow the consortium to rationally design further optimized vaccine conjugates.

 

Horizon MSCA ITN grants for several RIMLS teams

Willeke Daamen, Peter Friedl, Marien de Jonge, Yang Li and Roland van Rij collaborate with other companies and universities to create a new generation of entrepreneurial, multidisciplinary and intersectorially trained scientists. read more

Horizon MSCA ITN grants for several RIMLS teams

Skin Tissue Engineering and Regenerative Medicine: From skin repair to regeneration. Willeke Daamen and Toin van Kuppevelt, Reconstructive and regenerative medicine.
Total grant: 3,000 kEuro. Awarded Radboudumc: 531 kEuro.

INFLANET: Training European Experts in Inflammation: from the molecular players to animal models and the bedside. Peter Friedl, Cancer development and immune defense.
Total grant: 3,400 kEuro. Awarded Radboudumc: 531 kEuro.

CONSENSE: A game change in continuous biosensing: Molecularly engineered affinity-based nanoswitches for personal monitoring. Marien de Jonge, Infectious diseases and global health.
Total grant: 4,000 kEuro. Awarded Radboudumc: 266 kEuro.

ENLIGHT-TENplus: European Network Linking Informatics and Genomics of Helper T cells in Tissues. Yang Li, Infectious diseases and global health.
Total grant: 4,000 kEuro. Awarded Radboudumc: 266 kEuro.

VIROINF: Understanding (harmful) virus-host interactions by linking virology and bioinformatics. Ronald van Rij, Infectious diseases and global health.
Total grant: 3,400 kEuro. Awarded Radboudumc: 266 kEuro.

Charity Foundation grants

A selection of our Charity Foundation grants. read more

Charity Foundation grants

Dutch Kidney Foundation PhD grant

Targeting a novel paracrine signaling pathway between glomerular endothelium and podocytes to treat glomerular injury. Johan van der Vlag, Renal disorders.
Awarded Radboudumc: 260 kEuro.

Foundation for Prevention, Early diagnostics and E-health (PVE)

Vroegdiagnose van eierstokkanker met een nieuwe klasse van biomarkers: chondroitine sulfaat. Willeke Daamen and Toin van Kuppevelt, Reconstructive and regenerative medicine.
Awarded Radboudumc: 144 kEuro.

Dutch Cancer Society (KWF) grants

Research project, project # 12949. Cell surface protein organization determines therapeutic efficacy of cancer antibodies. Annemiek van Spriel, Cancer development and immune defence.
Awarded Radboudumc: 695 kEuro.

Unique high-Risk project, project # 12912: Metastatic mutualism: exploring the role of the microbiome on colorectal cancer liver metastasis (MetMut). Annemarie Boleij, Iris Nagtegaal and Daniele Tauriello, Tumours of the digestive tract.
Awarded Radboudumc: 176 kEuro.

COHERENT: COrrect diagnosis of HEmatological cancers for Right Treatment Decisions. Bert van der Reijden, Cancer development and immune defence.
Total grant: 1,600 kEuro. Awarded Radboudumc: 800 kEuro.

Hanarth Fonds

CUP fight: detecting the origin of metastatic disease. Iris Nagtegaal, Tumors of the digestive tract.
Awarded Radboudumc: 417 kEuro.

Transfer learning for immune cell landscape analysis in salivary gland cancer. Johannes Textor, Cancer development and immune defence. 
Awarded Radboudumc and Faculty of Science: 378 kEuro.

Martinus van Marum Prize

Life Sciences and Technology of the Royal Holland Society of Sciences and Humanities. Tom Schirris, Metabolic diseases.
Awarded Radboudumc: 12 kEuro.

Metakids-UMD

Development of -omics data infrastructure and bioinformatics solutions for data interpretation. Purva Kulkarni, Metabolic diseases.
Awarded Radboudumc: 220 kEuro.

PioNIER grant Nierstichting

Towards personalization of intravenous iron treatment in patients on maintenance hemodialysis. Dorine Swinkels and Tessel Galesloot, Renal disorders.
Awarded Radboudumc: 100 kEuro.

Prinses Beatrix Spierfonds grant

Advancing antisense therapy in DM1 in a patient-directed manner. Rick Wansink and Roland Brock, Nanomedicine.
Awarded Radboudumc: 280 kEuro.

Sarcoma Foundation of America

Unraveling the tumor immune microenvironment of angiosarcomas. Yvonne Versleijen-Jonkers, Rare cancers.
Awarded Radboudumc: 50 kEuro.

Stofwisselkracht grant

CRISPR/Cas9 knock-in complementation in fibroblasts of mitochondrial disease patients. Daan Panneman and Richard Rodenburg, Metabolic diseases.
Awarded Radboudumc: 25 kEuro.

Swiss Osteology Foundation

Tissue engineering using human umbilical cord blood stem cells to improve muscle, mucosa and skin regeneration following orofacial cleft surgery. Frank Wagener and Hans von den Hoff, Reconstructive and regenerative medicine.
Total grant: 100 kEuro. Awarded Radboudumc: 100 kEuro.

United for Metabolic diseases

Pyridoxine-dependent epilepsy (PDE-ALDH7A1) in adulthood: delineation of disease course & treatment effects. Clara van Karnebeek, Metabolic diseases.
Total grant: 10 kEuro. Awarded Radboudumc: 10 kEuro.

High throughput screening of protein expression to characterize genetic variants of unknown significance identified by WES/WGS. Richard Rodenburg, Jolein Gloerich and Omar Tutakhel, Metabolic diseases.
Total grant: 20 kEuro. Awarded Radboudumc: 20 kEuro.

ZonMw grants

A presentation of our ZonMw grants. read more

ZonMw grants

COVID-19 Second Wave call

A phase-2-study, pivotal for clinical development of lanadelumab for treatment of COVID-19. Frank van de Veerdonk, Infectious diseases and global health.
Total grant: 500 kEuro. Awarded Radboudumc: 500 kEuro.Integrative analysis of multi-omics longitudinal data to identify effective strategies for the prediction and treatment of COVID-19. Vinod Kumar Magadi Gopalaiah, Infectious diseases and global health.
Total grant: 500 kEuro. Awarded Radboudumc: 500 kEuro.

EJP-RD grant

Changing rare disorders of LysInE metabolism – CHARLIE. Clara van Karnebeek and Karlien Coene, Metabolic disorders.
Total grant: 1,200 kEuro. Awarded Radboudumc: 250 kEuro.
A reprogramming-based strategy for drug repositioning in patients with mitochondrial DNA-associated Leigh syndrome. Werner Koopman, Metabolic disorders.
Total grant: 2,000 kEuro. Awarded Radboudumc: 250 kEuro.Aniridia – Novel therapeutic tools to treat or prevent progressive cornea opacification. Jo Zhou, Reconstructive and regenerative medicine.
Total grant: 1,400 kEuro. Awarded Faculty of Science: 250 kEuro.

European Regional Development Fund (EFRO) and the province of Gelderland

Diagnostiek-in-3D: Verbeterde software voor genetische diagnostiek door gebruik van deep learning op 3-dimensionale eiwitstructuren. Martijn Huijnen, Metabolic diseases. 
Total grant: 636 kEuro. Awarded Radboudumc: 401 kEuro.

Health Holland grant

LSH-TKI + ZonMW: PLUGGING THE GAP: An enabling technology to prevent rupture of fetal membranes in fetal endoscopic surgery. Willeke Daamen, Frank Vandenbussche, Joris van Drongelen, Toin van Kuppevelt and Janneke Grutters, Reconstructive and regenerative medicine.
Total grant: 1,300 kEuro. Awarded Radboudumc: 1,300 kEuro.
LSH-SGF Humane Meetmodellen 1.0: Platform for Alternative Skin Tests for sustainable FUTURE science - PAST4FUTURE. Ellen van den Bogaard, Inflammatory diseases.
Total grant: 694 kEuro. Awarded Radboudumc: 594 kEuro.LSH-TKI EUREKA COVID-19 Network call: COVABELP. Development of an elastin-like peptide based theranostic platform technology to fight SARS-CoV-2.  William Leenders, Nanomedicine.
Total grant: 350 kEuro. Awarded Radboudumc: 140 kEuro.LSH-TKI: Match call: DETECTIVE. Detection and analysis of disease-driving T and B cell responses in tissues of patients with autoimmune disease for development of cell depletive treatment. Rogier Thurlings, Inflammatory diseases.
Awarded Radboudumc: 461 kEuro.LSH-TKI: Match call: IMAGEN. IMplementation of Advancements in GENetic Kidney Disease. Joost Hoenderop and Jeroen de Baaij, Renal disorders.
Total grant: 703 kEuro. Awarded Radboudumc: 350 kEuro.LSH-TKI: Kickstarter: Messenger RNA as a validator approach towards gene therapy of congenital chronic diseases. Roland Brock, Nanomedicine.
Total grant: 120 kEuro. Awarded Radboudumc: 20 kEuro.LSH-TKI: Kickstarter: APOLLO. Anti-fibrotic photodynamic therapy to relieve scleroderma. Marije Koenders, Inflammatory diseases.
Total grant: 119 kEuro. Awarded Radboudumc: 119 kEuro

Off Road grant

New strategies against virus transfer. Genoit Besson, Infectious diseases and global health.
Total grant: 100 kEuro. Awarded Radboudumc: 100 kEuro.

Can bacteria detect precursors of colon cancer? Annemarie Boleij, Tumours of the digestive tract.
Total grant: 100 kEuro. Awarded Radboudumc: 100 kEuro.New treatment for hereditary kidneys cyst. Sara Roig Merino, Renal disorders.
Total grant: 100 kEuro. Awarded Radboudumc: 100 kEuro.

Open Competition grant

Optimizing the design of dendritic cell vaccine immunotherapies. Jolanda de Vries, Cancer development and immune defence.
Total grant: 679 kEuro. Awarded Radboudumc: 548 kEuro.Defining H3K9 methylation regulatory pathways in monocyte and macrophage function in cardiovascular disease. Michiel Vermeulen, Cancer development and immune defence.
Total grant: 750 kEuro. Awarded Faculty of Science: 375 kEuro.

Personal grants

An overview of personal grants granted to our researchers. read more

Personal grants

ERC Proof of Concept grant

Improving the safety of live attenuated viral vaccines by exploiting RNA silencing pathways. Ronald van Rij, Infectious diseases and global health.
Awarded Radboudumc: 150 kEuro.

International Human Frontier Science Program (HFSP) Grant

T Cell Crowd Control. Johannes Textor, Cancer development and immune defense.
Awarded Radboudumc and Faculty of Science: 850 kEuro.

Kolff Startup Grant

PERSPECTIV study PERSpectives for PErsonalization of Complement-directed Therapy in patients with C3 glomerulopathy. Marloes Michels, Renal disorders.
Awarded Radboudumc: 100 kEuro.

Marie Curie Global Fellowship

OMG - OIT3: A novel Magnesiotropic Gene in Kidney. Maria Ibars Serra, Renal disorders.
Awarded Radboudumc: 94 kEuro.

Niels Stensen Fellowship

Personal grant to fund a postdoc at École polytechnique fédérale de Lausanne (EPFL) in Lausanne, Switzerland. Jorieke Weiden, Cancer development and immune defence.
Awarded Radboudumc: 58 kEuro.

NWO – Vici

Regeneration of diseased bone by biomaterials built from nanoparticles. Sander Leeuwenburgh, Reconstructive and regenerative medicine.
Awarded Radboudumc: 1,500 kEuro.

NWO – Veni

Time for a boost: metabolic potentiation of vaccines. Jorge Dominguez Andres, Infectious diseases and global health.
Awarded Radboudumc: 250 kEuro.RNA helicases - novel factors for virus transmission by mosquitoes. Pascal Miesen, Infectious diseases and global health.
Awarded Radboudumc: 250 kEuro.

NWO grants

NWO grants awarded to RIMLS researchers. read more

NWO grants

Open Competition Domain Science - XS grant

Small differences, large impact: how actin variants differentially control cancer cell migration. Koen van den Dries, Nanomedicine.
Awarded Radboudumc: 50 kEuro.

Identification of proteins that inactivate the female X chromosome. Hendrik Marks, Cancer development and immune defense.
Awarded Faculty of Science: 50 kEuro.

Defining the regulatory circuit that drives early development of virus-transmitting mosquitoes. Ronald van Rij, Infectious diseases and global health.
Awarded Radboudumc: 50 kEuro.

Novel peptide therapeutic to fight kidney stones. Jenny van der Wijst, Renal disorders.
Awarded Radboudumc: 50 kEuro.

Open Competition ENW-KLEIN grant

Molecular mechanisms of actin isoform usage in cancer cell migration. Koen van den Dries, Nanomedicne.
Awarded Radboudumc: 350 kEuro.

Synthetic affinity-based probes for proteome-wide identification of poly(ADP-ribosyl)-binding proteins. Michiel Vermeulen, Cancer development and immune defence.
Total grant: 720 kEuro. Awarded Faculty of Science: 360 kEuro.

Calmodulation of the epithelial calcium channels TRPV5 and TRPV6: Untangle a dual-faced mechanism. Jenny van der Wijst, Renal disorders.
Awarded Radboudumc: 350 kEuro.

Open call GROOT consortium

Active matter of cancer metastasis. Peter Friedl, Cancer development and immune defense.
Awarded Radboudumc: 300 kEuro.

Single Cell Analysis of Animal Development. Michiel Vermeulen, Cancer development and immune defense.
Awarded Faculty of Science: 330 kEuro.

TTW OTP grant

A nanomedicine platform to induce targeted eradication of tumors. Martijn Verdoes, Nanomedicine.
Awarded Radboudumc: 680 kEuro.

Veni

Time for a boost: metabolic potentiation of vaccines. Jorge Dominguez Andres, Infectious diseases and global health.
Awarded Radboudumc: 250 kEuro.

RNA helicases - novel factors for virus transmission by mosquitoes. Pascal Miesen, Infectious diseases and global health.
Awarded Radboudumc: 250 kEuro.

Vici

Regeneration of diseased bone by biomaterials built from nanoparticles. Sander Leeuwenburgh, Reconstructive and regenerative medicine.
Awarded Radboudumc: 1,500 kEuro.

Miscellaneous

NWO - ICI (Institute for Chemical Immunology) Amsterdam-Leiden-Nijmegen vaccine consortium: Synthetic peptide conjugates for cancer therapy. Martijn Verdoes, Nanomedine.
Total grant: 1,200 kEuro. Awarded Radboudumc: 305 kEuro.


An NWO Idea generator grant of the Dutch research agenda (Nationale Wetenschaps Agenda, NWA): Treating virus infections in mosquitoes – a novel strategy to prevent disease transmission. Rebecca Halbach, Infectious diseases and global health.
Total grant: 50 kEuro. Awarded Radboudumc: 50 kEuro.

Horizon 2020 grants

Horizon2020 grants obtained by our RIMLS researchers. read more

Horizon 2020 grants

3rd Health Programme (3HP)

HP-PJ-2019: ERN eUROGEN registry.  Wout Feitz, Reconstructive and regenerative medicine.
Total grant 200 kEuro. Awarded Radboudumc: 171 kEuro.

Consortium IMI2

IMI2-2018 call 5: ImmUniverse: Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies. Irma Joosten, Inflammatory diseases. 
Total grant: 15,500 kEuro. Awarded Radboudumc: 1,000 kEuro.IMI2-2019 call 19: Innodia-Harvest: Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA. Martin Gothardt, Tumors of the digestive tract.
Total grant: 6,000 kEuro. Awarded Radboudumc: 528 kEuro.

Consortium H2020

FET-OPEN: Heparin and heparan sulphate: from sequence determination to therapeutic strategies for Parkinson’s disease. Toin van Kuppevelt and Willeke Daamen, Reconstructive and regenerative medicine.
Total grant: 3,848 kEuro. Awarded Radboudumc: 592 kEuro.
MSCA ITN: Skin Tissue Engineering and Regenerative Medicine: From skin repair to regeneration. Willeke Daamen and Toin van Kuppevelt, Reconstructive and regenerative medicine.
Total grant: 3,000 kEuro. Awarded Radboudumc: 531 kEuro.
SC1-BHC-07-2019: PREMSTEM. Brain injury in the premature born infant: stem cell regeneration research network. Irma Joosten, Inflammatory diseases.
Total grant: 9,000 kEuro. Awarded Radboudumc: 322 kEuro.SC1-HCO-20-2020: ERICA. European Rare dIsease research Coordination and support Action. Wout Feitz, Reconstructive and regenerative medicine.
Total grant: 2,314 kEuro. Awarded Radboudumc: 65 kEuro.SC1-PHE-Coronavirus-2020: RECOVER - Rapid European COVID-19 Emergency research response. Frank van de Veerdonk, Infectious diseases and global health. 
Total grant: 5,000 kEuro. Awarded Radboudumc: 188 kEuro.MSCA ITN: INFLANET - Training European Experts in Inflammation: from the molecular players to animal models and the bedside. Peter Friedl, Cancer development and regenerative medicine.
Total grant: 3,400 kEuro. Awarded Radboudumc: 531 kEuro.MSCA ITN: VIROINF: Understanding (harmful) virus-host interactions by linking virology and bioinformatics. Ronald van Rij, Infectious diseases and global health.
Total grant: 3,400 kEuro. Awarded Radboudumc: 266 kEuro.MSCA ITN: CONSENSE: A game change in continuous biosensing: Molecularly engineered affinity-based nanoswitches for personal monitoring. Marien de Jonge, Infectious diseases and global health.
Total grant: 4,000 kEuro. Awarded Radboudumc: 266 kEuro.MSCA ITN: ENLIGHT-TENplus - European Network Linking Informatics and Genomics of Helper T cells in Tissues. Yang Li, Infectious diseases and global health.
Total grant: 4,000 kEuro. Awarded Radboudumc: 266 kEuro.H2020-SwafS-2020-1: ENABLing CAReErS: priming talent for success in Biomedicine. RIMLS institute.
Total grant: 319 kEuro. Awarded Radboudumc: 91 kEuro.

Joint Programming Initiative on Antimicrobial Resistance (JPI-EC-AMR)

Prevention of antibiotic resistance by TARGEted Treatment of pneumonia in children (TARGET). Quirijn de Mast and Marien de Jonge, Infectious diseases and global health.
Total grant: 787 kEuro. Awarded Radboudumc: 299 kEuro.

Marie Sklodowska-Curie Actions Individual Fellowships (MSCA IF)

VacTrack: Dissecting the protection mechanism of new generation vaccines by synchronizing systems biology with in vivo imaging. Marien de Jonge, Infectious diseases and global health. 
Total grant: 281 kEuro. Awarded Radboudumc: 281 kEuro.

Marie Sklodowska-Curie Actions Global Fellowships (MSCA GF)

OMG - OIT3: A novel Magnesiotropic Gene in Kidney. Maria Ibars Serra, Renal disorders. 
Total grant: 271 kEuro. Awarded Radboudumc: 94 kEuro.

Back to homepage